Nyxoah S.A. (NYXH)

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 25, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares on February 20, 2026. Share capital: EUR 6,511,048.19 Total number of securities carrying voting rights: 43,662,403 (all ordinary shares) Total number of voting rights (= denominator): 43,662,403 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 3,416,319 (all granted subscription rights; this number excludes 462,677 subscription rights that were issued but not yet granted) Total number of convertible bonds: 225 convertible bonds with a nominal value of EUR 91,500 per bond Total number of voting rights that can be obtained in case of conversion of all 225 convertible bonds at the current conversion price of EUR 5.00 per share: 4,117,500 * * * Contact: Nyxoah John Landry, CFOIR@nyxoah.com Attachment 2026 02 25 - Press release - Number of shares (ENG)

Healthcare Triangle (NASDAQ: HCTI - Get Free Report) and Nyxoah (NASDAQ: NYXH - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Valuation and Earnings This table compares Healthcare Triangle

Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East

Nyxoah SA (NASDAQ: NYXH - Get Free Report) saw a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 288,814 shares, an increase of 29.0% from the January 15th total of 223,806 shares. Based on an average daily volume of 61,235 shares, the days-to-cover ratio is

Nyxoah (NASDAQ: NYXH - Get Free Report) and Hinge Health (NYSE: HNGE - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership. Analyst Ratings This is a breakdown of recent ratings

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium – January 21, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an important investment in Belgium to further scale its manufacturing capacity to support its continued growth in the United States and international markets. In addition to its existing contract manufacturing operations in the United States, the Company will expand its manufacturing footprint in Wallonia, reflecting Nyxoah's long-standing relationship with the Belgium life science ecosystem.

Nyxoah SA (NYXH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), January 12, 2026 , 7:00 am CET / 1:00 am ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BNP Paribas Asset Management On January 8, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management SA.

Azenta (NASDAQ: AZTA - Get Free Report) and Nyxoah (NASDAQ: NYXH - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation. Volatility and Risk Azenta has a beta of 1.29,

Nyxoah Announces Issuance of First Tranche of Convertible Bonds Mont-Saint-Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the issuance of the first tranche of the convertible bond financing entered into with an entity managed by Heights Capital Management (“HCM”) of up to €45 million, as previously announced by the Company on November 13, 2025. Closing of the first tranche of the convertible bonds' issuance On December 18, 2025, the Company issued the first tranche of convertible bonds for a nominal amount of €22.5 million under the subscription agreement entered into with HCM on November 13, 2025, as amended and restated on December 16, 2025.

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy  in the Netherlands First Genio implants successfully performed at OLVG West and Zuyderland hospitals

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 2, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below. Robert Taub / BMI Estate On November 27, 2025, Nyxoah received a transparency notification from Robert Taub and related person BMI Estate.

Nyxoah secures a finalized CMS rule that sharply lifts 2026 reimbursement for Genio implants, opening fresh momentum for its OSA therapy.

Nyxoah to Participate in the Piper Sandler 37 th Annual Healthcare Conference

Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah's U.S. commercial rollout by strengthening hospital and ASC economics Mont-Saint-Guibert, Belgium – November 26, 2025, 7:45 am CET / 1:45 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has finalized its CY2026 Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgery Center (ASC) Rule. Within the final rule, CMS assigned CPT Code 64568, the code used for all Genio hypoglossal nerve stimulation (HGNS) implants, to New Technology Ambulatory Payment Classification (APC) 1580.

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6.504.688,76 Total number of securities carrying voting rights: 43,026,460 (all ordinary shares) Total number of voting rights (= denominator): 43,026,460 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 3,258,819 (all granted subscription rights; this number excludes 692,677 subscription rights that were issued but not yet granted) * * * Contact: Nyxoah John Landry, CFOIR@nyxoah.com Attachment 2025 11 20 - Press release - Number of shares (ENG)